Not for vaccine sales -- for sales of OTHER "thera
Post# of 148179
Merck and some other big companies have been making big noises about how they are about to have new monoclonal antibody treatments in Phase 2 or 3 (sorry, I don't remember which). The data they are claiming to have thus far looks good.
So, if they can delay therapeutics from small companies (and there are other small companies with other therapeutics that are focused on other things, like actually killing the virus) -- well gee, THEIR drug gets approved first and becomes SOC. Kind of the way Remdesivir did, even though it's not all that good.
But, as they used to say in MAD Magazine, at least it's really expensive.